Over the course of human civilization, viral infections have caused millions of human casualties worldwide, driving the development of antiviral drugs in a pressing need [1, 2].
As of April 2016, antiviral drugs have been approved to treat 9 human infectious diseases: HIV infections, hepatitis B (HBV), hepatitis C (HCV), human cytomegalovirus (HCMV), herpes simplex virus (HSV), human papillomavirus (HPV), respiratory syncytial virus (RSV), varicella-zoster virus (VZV), and influenza virus, albeit a definitive cure for most of them is yet to be discovered [3, 4]. Furthermore, there is still no antiviral drug or vaccine for over 200 human viruses afflicting populations worldwide .
The development of antiviral treatments remains a challenge due to the highly variable nature of virus genomes. Furthermore, the emerging drug resistance mutations remain a major cause of treatment failure, calling for a joint effort between scientific and industrial partners [4-8].
Viruses and cancer
Viruses account for ca. 20% of total human cancer cases. Although many viruses can cause tumors in animals, only seven of them are associated with human cancers and are considered oncogenic viruses: hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), Epstein Barr virus (EBV), human herpes virus 8 (HHV8), Merkel cell polyomavirus (MCPyV), and the human T-lymphotropic virus (HTLV-1). Both HBV and HCV cause around 80% of hepatocellular carcinoma (HCC), the most common cancer of the liver. High-risk HPV strains are the major causes of cervical cancer and other ano-genital neoplasms, head and neck tumors. EBV is associated with nasopharyngeal carcinoma, Hodgkin’s lymphoma, and Burkitt’s lymphoma. HHV8 (also called Kaposi’s sarcoma-associated herpesvirus, KSHV) is responsible for Kaposi’s sarcoma, often found in patients with immunodeficiency syndrome (AIDS). MCPyV causes Merkel cell carcinoma and HTLV-1 is the causative agent of adult T-cell lymphoma .
Recently, Herpes virus 6A (HHV-6A) and 7 (HHV-7) has been linked to Alzheimer’s disease .
Antiviral compounds with broad-spectrum activity against different virus genotypes or subtypes are in demand, because the effectiveness of most antiviral drugs is limited to only certain viral strains .
1.Clercq, E. D., Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004, 2, 704.
2.De Clercq, E., Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery 2002, 1, 13.
3.Woolhouse, M.; Scott, F.; Hudson, Z.; Howey, R.; Chase-Topping, M., Human viruses: discovery and emergence. Philosophical Transactions of the Royal Society B: Biological Sciences 2012, 367, (1604), 2864-2871.
4.De Clercq, E.; Li, G., Approved Antiviral Drugs over the Past 50 Years. Clin. Microbiol. Rev. 2016, 29, (3), 695-747.
5.Li, G.; Piampongsant, S.; Faria, N. R.; Voet, A.; Pineda-Peña, A.-C.; Khouri, R.; Lemey, P.; Vandamme, A.-M.; Theys, K., An integrated map of HIV genome-wide variation from a population perspective. Retrovirology 2015, 12, (1), 18.
6.Li, G.; Verheyen, J.; Rhee, S.-Y.; Voet, A.; Vandamme, A.-M.; Theys, K., Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology 2013, 10, (1), 126.
7.Boons, E.; Li, G.; Vanstreels, E.; Vercruysse, T.; Pannecouque, C.; Vandamme, A.-M.; Daelemans, D., A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antivir. Res. 2014, 112, 91-102.
8.Li, G., HIV genome-wide diversity, interaction and coevolution. HIV genoom diversiteit, interactie en co-evolutie 2014.
9.Luo, G. G.; Ou, J.-h. J., Oncogenic viruses and cancer. Virol. Sin. 2015, 30, (2), 83-84.
10.Readhead, B.; Haure-Mirande, J.-V.; Funk, C. C.; Richards, M. A.; Shannon, P.; Haroutunian, V.; Sano, M.; Liang, W. S.; Beckmann, N. D.; Price, N. D.; Reiman, E. M.; Schadt, E. E.; Ehrlich, M. E.; Gandy, S.; Dudley, J. T., Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron.